September 25, 2023 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) today announces that the Company has elected Mr. Carl-Åke Carlsson as its new Chairman of the Board of Directors.

2023年9月25日（丹麦哥本哈根）。Zerion Pharma A/S（“Zerion”）今天宣布该公司当选Carl-Åke Carlsson先生为新董事会主席。

Mr. Carlsson brings over three decades of leadership and strategic experience in the pharmaceutical industry and embodies Scandinavian diversity: Born in Norway with Swedish ancestry and having spent over a decade living and working in Denmark. Carl-Åke joins Zerion’s Board after 15 years as CEO of Xellia Pharmaceuticals, specializing in anti-infective and critical care treatments.

Carlsson先生在制药业带来了三十年的领导和战略经验，体现了斯堪的纳维亚的多样性：出生于挪威，有瑞典血统，在丹麦生活和工作十多年。Carl-Åke在担任Xellia Pharmaceuticals首席执行官15年后加入Zerion的董事会，专门从事抗感染和重症监护治疗。

Under his leadership, Xellia transitioned from a Scandinavian entity to a global contender, boasting annual sales to USD 300 million and a robust team of around 1,800 employees..

在他的领导下，Xellia从斯堪的纳维亚实体过渡到全球竞争者，拥有3亿美元的年销售额和大约1800名员工的强大团队。。

'We are excited to welcome Mr. Carlsson to our leadership team,' said Ole Wiborg, CEO of ZERION, and continues: 'ZERION stands in front of significant opportunities on the path to commercialise our Dispersome® technology platform, and I am convinced that Mr. Carlsson will be able to make a great contribution in both setting and implementing the strategic direction to exploit these opportunities to their maximum.”.

“我们很高兴欢迎Carlsson先生加入我们的领导团队，”ZERION首席执行官Ole Wiborg说，并继续说：“ZERION在将我们的Dispersome®技术平台商业化的道路上占据了重要的机会，我相信先生。卡尔森将能够在制定和实施战略方向方面做出巨大贡献，最大限度地利用这些机会。”。

For his part, Mr. Carlsson commented, 'I'm excited to join ZERION in this important role. I believe the company’s technology holds immense potential, and I'm eager to contribute to the company's growth and innovation.'

对于他而言，卡尔森先生评论说：“我很高兴加入ZERION担任这一重要角色。我相信公司的技术具有巨大的潜力，我渴望为公司的成长和创新做出贡献

ZERION’s Dispersome® technology has proven to be very efficient in improving the solubility and bioavailability of small molecule drugs. ZERION has established partnerships with a significant number of large pharmaceutical companies that are exploiting the Dispersome® platform for both new chemical entities as well as currently marketed drugs.

事实证明，ZERION的Dispersome®技术在提高小分子药物的溶解度和生物利用度方面非常有效。ZERION已与大量大型制药公司建立合作关系，这些公司正在为新化学实体和目前销售的药物开发Dispersome®平台。

Some of these partnerships are now proceeding into the clinical phase..

其中一些合作伙伴关系正在进入临床阶段。。

Before his tenure at Xellia, Mr. Carlsson held several leadership roles at Alpharma (NYSE:ALO). For a decade, he was integral to the top leadership, overseeing business within pharmaceutical retail, specialty institutional markets, and the extensive global B2B sectors. Mr. Carlsson is also serving at prominent board positions, including the biotech company Vectron Biosolutions and Lecka Alpha Trading LP..

在Xellia任职之前，Carlsson先生在Alpharma（纽约州：ALO）担任过几名领导职务。十年来，他一直是最高领导层的一员，负责监督制药零售，专业机构市场和广泛的全球B2B行业的业务。Carlsson先生还担任着名董事会成员，包括生物技术公司Vectron Biosolutions和Lecka Alpha Trading LP。。

About Zerion Pharma A/S

关于Zerion Pharma A/S

ZERION develops its own proprietary drug formulations and offers its Dispersome® technology platform to established pharma companies as a means to solve their challenging drug solubility problems. By applying ZERION’s technology, the solubility of poorly soluble compounds may be greatly enhanced, which improves their oral bioavailability and thereby therapeutic outcomes for the patients.  .

ZERION开发自己专有的药物配方，并为已建立的制药公司提供其Dispersome®技术平台，以解决其具有挑战性的药物溶解度问题。通过应用ZERION技术，可以大大提高难溶性化合物的溶解度，从而提高其口服生物利用度，从而为患者提供治疗效果。  .

ZERION was established in 2019 as a spin-out from the University of Copenhagen based on almost a decade of research.

基于近十年的研究，ZERION成立于2019年，是哥本哈根大学的分拆产品。

For more information, please visit www.zerion.eu or contact:

欲了解更多信息，请访问www.zerion.eu或联系：

Ole Wiborg, CEO                         Mobile: +45 40 96 80 18                       E-mail: info@zerion.eu

Ole Wiborg，首席执行官手机：+45 40 96 80 18电子邮件：info@zerion.eu